Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05687266 · ClinicalTrials.gov registry record · Phase 3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
A Phase 3 study of NSCLC, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,350
- Enrollment target
- 20
- Study locations
NCT05687266: Active Phase 3 study of NSCLC, sponsored by AstraZeneca.
NCT05687266 is a Phase 3 study of NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,350 participants, above the 205-participant average among 71 other NSCLC trials with a reported enrollment target (559% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05687266, a Phase 3 study of NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
Primary Outcome
PFS is defined as time from randomisation until progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Durvalumab
- DRUG Datopotamab deruxtecan
Study Locations (20)
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
- Research Site - St. Petersburg
- Research Site - West Palm Beach
Arkansas
- Research Site - Hot Springs
- Research Site - Little Rock
- Research Site - Springdale
California
- Research Site - Fountain Valley
- Research Site - Los Angeles
- Research Site - Orange
Iowa
- Research Site - Bettendorf
- Research Site - Iowa City
- Research Site - Waukee
Arizona
- Research Site - Phoenix
- Research Site - Tucson
Louisiana
- Research Site - Baton Rouge
- Research Site - Covington
Colorado
- Research Site - Boulder
Illinois
- Research Site - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,350 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
What the registry record for NCT05687266 still lists
NCT05687266 is an interventional study that assigns participants to a tested intervention. Its 1,350 participants enrollment target places it among the larger protocols in the corpus, above the 205-participant average among 71 other NSCLC trials with a reported enrollment target (559% higher).
The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05687266 names 20 study sites across 9 states, led by Florida, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT05687266 about?
NCT05687266 is a clinical study titled "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations". This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line t...
What is the current status of trial NCT05687266?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,350 participants. The study started on 2022-12-29. Estimated completion is 2027-11-01.
What conditions does trial NCT05687266 study?
This clinical trial studies the following conditions: NSCLC.
What interventions are being tested in trial NCT05687266?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Durvalumab (DRUG), Datopotamab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05687266?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05687266 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05687266's enrollment target sits among peer trials
1,350 1st of 71 higher than 71 of 71 other NSCLC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NSCLC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
RECRUITING · Phase 3
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
RECRUITING · Phase 3
-
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI